Signaturefd, LLC Alector, Inc. Transaction History

Signaturefd, LLC

$4.91 Billion
Q2 2024

A detailed history of Signaturefd, LLC transactions in Alector, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 418 shares of ALEC stock, worth $1,901. This represents 0.0% of its overall portfolio holdings.

Number of Shares

418

Previous 1,471 71.58%

Holding current value

$1,901

Previous $8,000 87.5%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$4.19 - $6.23 $4,412 - $6,560	-1,053 Reduced 71.58%	418 $1,000
Q1 2024 May 03, 2024	BUY	$5.69 - $8.08 $1,138 - $1,616	200 Added 15.74%	1,471 $8,000
Q4 2023 Jan 31, 2024	SELL	$3.77 - $8.39 $2,167 - $4,824	-575 Reduced 31.15%	1,271 $10,000
Q3 2023 Nov 03, 2023	BUY	$5.2 - $8.77 $2,470 - $4,165	475 Added 34.65%	1,846 $11,000
Q2 2023 Aug 01, 2023	BUY	$5.86 - $7.93 $3,416 - $4,623	583 Added 73.98%	1,371 $8,000
Q1 2023 Apr 28, 2023	BUY	$5.85 - $9.84 $4,165 - $7,006	712 Added 936.84%	788 $4,000
Q4 2022 Jan 27, 2023	SELL	$6.88 - $9.55 $1,114 - $1,547	-162 Reduced 68.07%	76 $0
Q3 2022 Nov 08, 2022	BUY	$8.19 - $13.2 $1,949 - $3,141	238 New	238 $2,000
Q2 2022 Aug 10, 2022	SELL	$7.65 - $14.24 $826 - $1,537	-108 Closed	0 $0
Q1 2022 May 02, 2022	SELL	$13.02 - $20.78 $117 - $187	-9 Reduced 7.69%	108 $2,000
Q4 2021 Jan 25, 2022	BUY	$19.35 - $25.54 $174 - $229	9 Added 8.33%	117 $2,000
Q4 2020 Feb 11, 2021	BUY	$9.4 - $16.7 $1,015 - $1,803	108 New	108 $2,000
Q2 2020 Jul 30, 2020	SELL	$21.87 - $33.11 $1,509 - $2,284	-69 Closed	0 $0
Q1 2020 Apr 23, 2020	BUY	$16.25 - $35.28 $1,121 - $2,434	69 New	69 $2,000

Others Institutions Holding ALEC

# of Institutions

165

Shares Held

58.1M

Call Options Held

57K

Put Options Held

14.9K

View Full List

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $376M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account